PCSK9 and chronic obstructive pulmonary disease: Furthermore, new cholesterol-targeting therapies must be extensively investigated in COPD subjects, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and inclisiran, a small interfering RNA therapy.